Statement: Every patient in the primary trial and the secondary trial suffered at least 1 Treatment-emergent adverse event over a span of 2 years.
Primary_evidence: Outcome Measurement:    Incidence of Treatment-emergent AE's   [Not Specified]   Time frame: 2 years Results 1:    Arm/Group Title: MM-111 + Herceptin   Arm/Group Description: MM-111 will be combined with Herceptin   MM-111 and Herceptin: For Phase 1: Dose escalation cohorts, MM-111 and Herceptin are administered weekly or bi-weekly via IV   Overall Number of Participants Analyzed: 16   Measure Type: Number   Unit of Measure: participants  16
Secondary_evidence: Outcome Measurement:    Number of Participants With Trastuzumab-Induced Cardiotoxicity After 52 Weeks of Treatment   Reduction in incidence of trastuzumab-induced cardiotoxicity after 52 weeks of treatment as measured by preservation of Left Ventricular Ejection Fraction (LVEF). Number of Patients who experienced a cardiotoxicity.   Time frame: 2 years Results 1:    Arm/Group Title: Arm I Lisinopril   Arm/Group Description: Patients receive oral lisinopril once daily.   lisinopril: Given orally   Overall Number of Participants Analyzed: 152   Measure Type: Count of Participants   Unit of Measure: Participants  45  29.6% Results 2:    Arm/Group Title: Arm II Coreg CR     Arm/Group Description: Patients receive oral Coreg CR   once daily.   Coreg CR  : Given orally   Overall Number of Participants Analyzed: 147   Measure Type: Count of Participants   Unit of Measure: Participants  43  29.3%